Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.53 |
| ▸ | PDE8A | O60658 | 10/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.46 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161381 | 0.87 | YTHDC1 (0.55) | YTHDC1PDE8AADORA2ATMIGD3ADORA1 | |
| SCHEMBL3441053 | 0.81 | ADORA2A (0.65) | YTHDC1PDE8ACDK1ADORA2ATMIGD3 | |
| SCHEMBL19575728 | 0.80 | YTHDC1 (0.42) | YTHDC1PDE8ACDK1ADORA2ATMIGD3 | |
| SCHEMBL5162133 | 0.79 | ADORA2A (0.52) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL14024978 | 0.79 | ADORA2A (0.62) | PDE8ACDK1ADORA2ATMIGD3ADORA1 | |
| SCHEMBL5160855 | 0.78 | ADORA2A (0.50) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL5164048 | 0.78 | ADORA2A (0.50) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL5160523 | 0.78 | ADORA2A (0.49) | ADORA2ATMIGD3ADORA1ADORA2BPDE4A | |
| SCHEMBL5357328 | 0.78 | ADORA2A (0.77) | CDK1ADORA2ATMIGD3ADORA1ADORA2B | |
| SCHEMBL5164692 | 0.78 | ADORA2A (0.74) | ADORA2ATMIGD3ADORA1ADORA2BCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200615-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | Gilead Palo Alto, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009052310-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ZABLOCKI JEFF | 2009-04-16 | — | — | US | disclosed |
| US-7238700-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1456209-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1401837-B1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040209899-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (IN) | 2004-10-21 | — | — | US | disclosed |
| US-6770651-B2 | THERAPY FOR ASTHMA, DIARRHEA | PALLE VENKATA (US) | 2004-08-03 | — | — | US | disclosed |
| EP-1401837-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030064999-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (US) | 2003-04-03 | — | — | US | disclosed |
| WO-2003006465-A1 | PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002566-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064999-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | YTHDC1 4281/4885PDE8A 221/4885CDK1 3001/4885 |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA2A, ADORA2B | YTHDC1 1919/4885PDE8A 450/4885CDK1 2428/4885 |
| US-20040209899-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | YTHDC1 2103/4885PDE8A 504/4885CDK1 2097/4885 |
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | YTHDC1 2858/4885PDE8A 229/4885CDK1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.